Skip to main content
https://www.youtube.com/watch?v=uyIRHn0AmNA

Groundbreaking cell and gene therapy manufacturing and commercialization

New commercial-scale manufacturing facility for APAC market supply

Cell Therapies is excited to announce the opening of its new cell and gene therapy GMP manufacturing facilities.

As Australia’s only biomedical manufacturing facility where CAR T-cells and other “living” cancer therapies can be made at a commercial scale, this expansion increases capacity to support high throughput manufacture of clinical trial and commercial cell and gene therapy products for Australian patients and the Asia Pacific market. 

The facility expansion includes three large-scale high-throughput GMP manufacturing suites suitable for supply of late-phase clinical trial and commercial products with a production capacity of up to 2,000 patient doses per year.  

We’ve been manufacturing cutting edge cell and gene therapies for over 20 years

cell therapies is an Australian-based, globally-active commercial contract development and manufacturing company, specializing in cell therapy, gene therapy, regenerative medicine, and cellular immunotherapy products.

A leader in this groundbreaking field, our expert team and world-class facilities have been developing and manufacturing cutting edge treatments for cancer and rare diseases on behalf of local and international clients since 2003.

Explore our services

Cell Therapies has extensive experience in the development and commercialization of cell and gene therapies for the Australian and global markets.

Apheresis Management

Over 18 years’ experience managing apheresis collections under GMP quality oversight

Contract Manufacturing

Licensed GMP manufacturing and process development for clinical trials and commercial supply

Clinical Trial Support

Enabling global clinical trial establishment by assisting from trial design to regulatory submission

Consulting and Advisory

The expertise to advance your program from clinical trial through to commercial supply

Industry-leading GMP facility delivering cell and gene therapies from Australia to the world

cell therapies GMP facility is located in Melbourne, Australia, and has manufacturing licences for clinical and commercial supply from Australia’s regulatory agency, the Therapeutic Goods Administration (TGA). Our facility also complies with global regulatory standards for US (FDA), Europe (EMA), Japan (MHLW) and other jurisdictions.

Our Partners and Affiliations

Latest News

Arovella Therapeutics partners with Cell Therapies to develop its ALA-101 manufacturing process for cancer clinical trials

| News | No Comments
Cell Therapies Pty Ltd is partnering with Arovella Therapeutics (ASX: ALA) to develop the manufacturing process for Arovella’s ALA-101 product candidate to treat cancer patients in upcoming clinical trials. The…

Cell Therapies Pty Ltd is delighted to announce the appointment of Dr Bev Menner as the company’s new Chief Executive Officer.

| News | No Comments
Cell Therapies Pty Ltd, a leading provider of cell and gene therapy products in the Asia Pacific region, is delighted to announce the appointment of Dr Bev Menner as the company’s new…

New commercial-scale cell and gene therapy manufacturing facility for APAC market supply

| News | No Comments
Cell Therapies Pty Ltd. is excited to announce the opening of new cell and gene therapy GMP manufacturing facilities to meet future patient demand at the Peter MacCallum Cancer Centre.…

Cell Therapies to manufacture BioNTech’s product candidate BNT211 in Australia

| News | No Comments
Cell Therapies Pty Ltd (CTPL) has been engaged by Germany-based biopharmaceutical company BioNTech SE (BioNTech) to manufacture BioNTech’s novel CAR-T cell therapy candidate BNT211 in Australia. The candidate is an…

Contact the Cell Therapies Team today

Reach out to our expert team by entering your details below and we will get into contact with you.